Clinical Trials

160 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

300 enrolled

Tumor-Agnostic

Neoplasms

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Phase 1 Unknown

22 enrolled

NSCLC

NCT04575415 2020-10-20

BELLA

Unknown

272 enrolled

NSCLC

NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

200 enrolled

Advanced NSCLC With EGFR Mutation

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01405079 2020-02-18

ADJUVANT

222 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04028778 2019-11-08

FL-ALTER

310 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

120 enrolled

NSCLC

NCT00282100 2019-04-16

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

40 enrolled

Gastrointestinal

Liver Neoplasms

NCT02929693 2019-04-11

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

198 enrolled

Tumor-Agnostic

Neoplasms

NCT03766490 2019-01-30

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

66 enrolled

Non-Small-Cell Lung

NCT03656393 2018-09-04

RCTACSCNSCLC

48 enrolled

NSCLC

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

9 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

152 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT03486496 2018-04-03

Geber

Adenocarcinoma of Lung

NCT03399669 2018-01-16

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03381430 2017-12-22

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Lung Neoplasms

NCT03264794 2017-08-29

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Phase 4 Unknown

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03123484 2017-04-21

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02282267 2017-02-24

Benefit

188 enrolled

Adenocarcinoma of Lung

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02951637 2016-11-01

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

300 enrolled

Adenocarcinoma of Lung, Adenocarcinoma

NCT02930954 2016-10-13

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

188 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02013089 2016-08-30

GITIC

Gastrointestinal

Gastrointestinal Neoplasms

NCT02824458 2016-07-07

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

246 enrolled

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

NCT02788058 2016-06-02

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

76 enrolled

Adenocarcinoma of Lung

NCT02031601 2016-03-29

TCL-1

Phase 4 Unknown

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02321293 2015-09-02

CURCUMIN

Phase 1 Unknown

20 enrolled

Lung Neoplasms

NCT01955421 2015-07-03

NSCLC EGFR TKI

224 enrolled

Advanced Stage Non Small Cell Lung Cancer

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Phase 2/3 Unknown

380 enrolled

NSCLC

NCT02338011 2015-01-26

EGFR

Phase 2/3 Unknown

210 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02319577 2014-12-18

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00006048 2013-12-19

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00006049 2013-12-19

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Unknown

16 enrolled

Dermatologic

Skin Neoplasms

NCT00809237 2013-12-10

Hydroxychloroquine and Gefitinib to Treat Lung Cancer

Phase 1/2 Unknown

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01024712 2013-08-12

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

26 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00955695 2013-08-02

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

242 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01510990 2013-01-29

First Line Gefitinib by FDG-PET Metabolic Response

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

200 enrolled

EGFR Mutation Positive Non-small Cell Lung Cancer

NCT01755923 2012-12-24

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01749072 2012-12-13

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01746277 2012-12-10

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01732276 2012-12-03

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01502202 2012-06-20

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

162 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01391260 2011-08-02

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

30 enrolled